Loading…
Loading…
MMED (MiniMed Group, Inc. Common Stock) is a recent IPO.
It began trading on March 5, 2026, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
MMED does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MMED and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MMED and 80,000+ other tickers.
See exactly how MMED's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MMED and 80,000+ other tickers.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
A new product introduction helped lift the top line. It seems there's more where that came from, with new product introductions scheduled over the coming months.
MiniMed's pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED's Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off.
Deutsche Bank AG bought a new stake in MiniMed Group Inc (NASDAQ: MMED) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,073 shares of the company's stock, valued at approximately $420,000. Separately, Bank of New York
MiniMed Group Inc (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.
MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcript